18 MARCH 2017 | PHARMACEUTICAL PROCESSING
CMO Roundtable: What’s Next for
the Contract Manufacturing Industry
An exclusive roundtable with Cambrex and West Pharmaceutical Services, Inc.
on contract manufacturing as a whole, how the space has changed, upcoming
trends, as well as what the industry will look like in the coming years.
By Meg La Torre-Snyder, Editor
2016 saw a continued increase in outsourcing
manufacturing operations to contract
manufacturers in order for pharmaceutical
companies to cut back on in-house costs and
capacity while maintaining quality and improving
time to market. With increased pressures for
companies to reduce cost while still expanding
core competencies (such as R&D) and marketing,
outsourcing continues to make a name for itself in
A number of contract manufacturing
organizations (CMOs) and contract development
and manufacturing organizations (CDMOs)
have expanded their offerings to meet market
demands, becoming even more versatile as the
demand for a greater availability of drugs and
swifter drug approvals increases (with more
regulations in place).
Meanwhile, some contract manufacturers have
found their niche in the market and continue to
make a name for themselves within that space.
CMO Cambrex focuses solely upon small
molecule chemical development and manufacturing.
With ambitions to become the number one small
molecule CMO in the pharmaceutical industry,
Cambrex has recently facilitated the building of a